Member Profile

Dr. Louis M. Aledort

Dr. Aledort is a chaired Professor of Medicine at the Mount Sinai School of Medicine. He was educated and trained at Albert Einstein College of Medicine, Universities of Rochester and Virginia, and spent two years at the National Institute of Health. He has spent his career in the area of bleeding disorders.

He has served as consultant to the World Health Organization, Pan American Health Organization, House Ways & Means Committee. He has chaired and/or been a member of the practice committees of the American Society of Hematology and American College of Physicians.

He has written more than 400 articles on several aspects of bleeding and clotting disorders. Emphasis has been on the supply availability and affordability of blood products. He has been involved in developing health care programs and their underwriting in developing nations. Dr. Aledort has consulted for CSL Behring, American Red Cross, and Baxter BioScience.

He has received the Lifetime Achievement Awards from the Hemostasis and Thrombosis Research Society and from the Albert Einstein College of Medicine.

Key Publications
  1. Aledort LM. Off-Label Use of Recombinant Activated Factor VII -Safe or Not Safe? N Engl J Med 2010; 363: 19: 1853-1854.
  2. Aledort LM. Another role for the VW molecule. Haemophilia 2012; 18: 246-247.
  3. Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost 2011; 9: 2180-2192.

Current Positions/Chairs:

  • Chair
    The Mary Weinfeld Professor of Clinical Research in Hemophilia at Mount Sinai School of Medicine
  • Co-Chair
    International Prophylaxis Study Group (IPSG)

Key Institutions

  • Mount Sinai School of Medicine
    New York, USA

Research Interests

  • Healthcare economics
  • Bleeding and clotting disorders
  • Clinical trials


July 1, 2012

Tertiary prophylaxis in adults: What is the rationale?

Gringeri A, Lambert T, Street A, and Aledort L. on behalf of the Adolescent/Adult Prophylaxis Study Group of the International Prophylaxis Study Group.
Haemophilia 2012 Sept; 18 (5): 722-728
February 22, 2012

Why should we Care about Quality of Life in Hemophilia?

Aledort L, Bullinger M, von Mackensen S, Wasserman J, and Young NL. on behalf of the Health Related Quality of Life Expert Working Group of the International Prophylaxis Study Group.
Haemophilia 2012; May 18 (3) : e154 – e157.
September 10, 2007

The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) Symposium.

Feldman BM, Aledort L, Bullinger M, Delaney FM, Doria AS, Funk S, Giangrande P, Lundin B, Manco-Johnson M, Miners A, Scriba PC, Srivastava A, Schramm W and Blanchette VS.
Haemophilia 2007 Nov; 13 (6): 745-749.
March 4, 2006

Are randomized clinical trials the only truth? Not always

Aledort L, Ljung R, and Blanchette V on behalf of the International Prophylaxis Study Group (IPSG)
Journal of Thrombosis and Haemostasis 2006 Mar; 4 (3): 503 - 504.